157 related articles for article (PubMed ID: 23408949)
41. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases.
Matsushita Y; Cleary KR; Ota DM; Hoff SD; Irimura T
Lab Invest; 1990 Dec; 63(6):780-91. PubMed ID: 1979361
[TBL] [Abstract][Full Text] [Related]
42. [Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens].
Larena A; Vierbuchen M; Schröder S; Larena-Avellaneda A; Hadshiew I; Fischer R
Langenbecks Arch Chir; 1996; 381(2):102-13. PubMed ID: 8649124
[TBL] [Abstract][Full Text] [Related]
43. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
Brodzik R; Glogowska M; Bandurska K; Okulicz M; Deka D; Ko K; van der Linden J; Leusen JH; Pogrebnyak N; Golovkin M; Steplewski Z; Koprowski H
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8804-9. PubMed ID: 16720700
[TBL] [Abstract][Full Text] [Related]
44. The x-ray structure of an anti-tumour antibody in complex with antigen.
Jeffrey PD; Bajorath J; Chang CY; Yelton D; Hellström I; Hellström KE; Sheriff S
Nat Struct Biol; 1995 Jun; 2(6):466-71. PubMed ID: 7664109
[TBL] [Abstract][Full Text] [Related]
45. A possible role for metallic ions in the carbohydrate cluster recognition displayed by a Lewis Y specific antibody.
Farrugia W; Scott AM; Ramsland PA
PLoS One; 2009 Nov; 4(11):e7777. PubMed ID: 19901987
[TBL] [Abstract][Full Text] [Related]
46. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
[TBL] [Abstract][Full Text] [Related]
47. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
48. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
Dettke M; Loibner H
Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
[TBL] [Abstract][Full Text] [Related]
49. Molecular recognition of the Lewis Y antigen by monoclonal antibodies.
Blaszczyk-Thurin M; Murali R; Westerink MA; Steplewski Z; Co MS; Kieber-Emmons T
Protein Eng; 1996 May; 9(5):447-59. PubMed ID: 8795045
[TBL] [Abstract][Full Text] [Related]
50. Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells.
Gao S; Liu Q; Wang X; Lin B; Zhang S
Med Oncol; 2010 Sep; 27(3):960-7. PubMed ID: 19771531
[TBL] [Abstract][Full Text] [Related]
51. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
[TBL] [Abstract][Full Text] [Related]
52. Specificity and immunobiological properties of monoclonal antibody IMH2, established after immunization with Le(b)/Le(a) glycosphingolipid, a novel extended type 1 chain antigen.
Ito H; Tashiro K; Stroud MR; Orntoft TF; Meldgaard P; Singhal AK; Hakomori S
Cancer Res; 1992 Jul; 52(13):3739-45. PubMed ID: 1377598
[TBL] [Abstract][Full Text] [Related]
53. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.
Tolcher AW; Sugarman S; Gelmon KA; Cohen R; Saleh M; Isaacs C; Young L; Healey D; Onetto N; Slichenmyer W
J Clin Oncol; 1999 Feb; 17(2):478-84. PubMed ID: 10080588
[TBL] [Abstract][Full Text] [Related]
54. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.
Yelton DE; Rosok MJ; Cruz G; Cosand WL; Bajorath J; Hellström I; Hellström KE; Huse WD; Glaser SM
J Immunol; 1995 Aug; 155(4):1994-2004. PubMed ID: 7636250
[TBL] [Abstract][Full Text] [Related]
55. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
56. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
Herbertson RA; Tebbutt NC; Lee FT; MacFarlane DJ; Chappell B; Micallef N; Lee ST; Saunder T; Hopkins W; Smyth FE; Wyld DK; Bellen J; Sonnichsen DS; Brechbiel MW; Murone C; Scott AM
Clin Cancer Res; 2009 Nov; 15(21):6709-15. PubMed ID: 19825951
[TBL] [Abstract][Full Text] [Related]
57. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
[TBL] [Abstract][Full Text] [Related]
58. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
59. Glycan array analysis of the antigen repertoire targeted by tumor-binding antibodies.
Gildersleeve JC; Wang B; Achilefu S; Tu Z; Xu M
Bioorg Med Chem Lett; 2012 Nov; 22(22):6839-43. PubMed ID: 23063402
[TBL] [Abstract][Full Text] [Related]
60. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody.
Murali R; Kieber-Emmons T
J Mol Recognit; 1997; 10(6):269-76. PubMed ID: 9770651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
